# Immune endotyping and gene expression profile of patients with chronic rhinosinusitis with nasal polyps in the aspirin-exacerbated respiratory disease (AERD) and the non-AERD subgroups

**Authors:** Javad Nazari, Faezeh Shahba, Negin Jafariaghdam, Saleh Mohebbi, Saba Arshi, Mohammad Hassan Bemanian, Morteza Fallahpour, Sima Shokri, Fatemeh Atashrazm, Saeed Amini, Maryam Roomiani, Mahnaz Jamee, Pegah Babaheidarian, Majid Khoshmirsafa, Mohammad Nabavi

PMC · DOI: 10.1186/s13223-024-00876-w · 2024-02-15

## TL;DR

This study compares immune profiles and gene expression in patients with chronic rhinosinusitis with nasal polyps, focusing on those with and without aspirin-exacerbated respiratory disease.

## Contribution

The study identifies distinct immune and gene expression patterns in AERD versus non-AERD CRSwNP patients, highlighting Th2 inflammation in AERD.

## Key findings

- AERD patients showed higher infiltration of eosinophils, neutrophils, and plasma cells in nasal polyps compared to non-AERD patients.
- Gene expression levels of GATA3, IL4, IL5, and IL17 were significantly higher in the AERD group.
- Th2 inflammation appears to predominate in AERD patients based on gene and immune profile differences.

## Abstract

Chronic Rhinosinusitis (CRS) is a paranasal sinus inflammatory disease and is divided into two subgroups defined as CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRSwNP displays a T helper (Th)2 biased phenotype, and based on sensitivity or tolerance to aspirin or non-steroidal anti-inflammatory drugs (NSAID), is further subdivided into Aspirin-exacerbated respiratory disease (AERD) and non-AERD groups. Considering the challenge of diagnosis and treatment in patients with CRSwNP, particularly the AERD subtype, and the significance of endotyping in these patients, we examined the immune profile and endotyping based on gene expression analysis in the AERD and the non-AERD groups of patients with CRSwNP.

In this study, 21 patients were enrolled and were categorized into AERD (N = 10) and non-AERD (N = 11) groups based on their sensitivity to aspirin. After the special washing period, nasal polyps were biopsied in both groups, and the infiltration of eosinophils, neutrophils, plasma cells, and lymphocytes was compared between the AERD and the non-AERD groups. Also, gene expression levels of transcription factors including Tbet, GATA3, RoRγt, and FoxP3 and inflammatory cytokines including interleukin (IL)1β, IL1RAP (IL1 receptor accessory protein), IL2, IL4, IL5, IL10, IL13, IL17, TNFα, and IFNγ were investigated by quantitative Real-time PCR (qRT-PCR). Statistical analyses were performed using analytical tests including Kolmogorov–Smirnov, Mann-Whitney, and T-test. A P value less than 0.05 was considered statistically significant.

The mean ± SD age of the studied groups was 37 ± 8.7 years old (21–50) for the AERD, and 40.4 ± 7.7 years old (31–52) for the non-AERD. LMS/EPOS/SNOT scores and pulmonary function tests showed no difference between the two groups. Serum immunoglobulin E (IgE) levels were found to be higher in patients with AERD (p = 0.04), however, the peripheral blood counts of eosinophils were comparable in the two groups. In the histopathologic analysis, the AERD group showed higher percentages of eosinophils (p = 0.04), neutrophils (p = 0.04), and plasma cells (p = 0.04) than the non-AERD group. Additionally, the gene expression levels of GATA3 (p = 0.001), IL4 (p = 0.04), IL5 (p = 0.007), and IL17 (p = 0.03) were significantly higher in the AERD than the non-AERD groups.

Higher gene expression levels of GATA3, IL4, IL5, and IL17 were observed in the AERD group compared with the non-AERD group. These findings point to distinct patterns of inflammation in patients with AERD, with a predominance of Th2 inflammation.

The online version contains supplementary material available at 10.1186/s13223-024-00876-w.

## Linked entities

- **Genes:** TBX21 (T-box transcription factor 21) [NCBI Gene 30009], GATA3 (GATA binding protein 3) [NCBI Gene 2625], FOXP3 (forkhead box P3) [NCBI Gene 50943], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL1RAP (interleukin 1 receptor accessory protein) [NCBI Gene 3556], IL2 (interleukin 2) [NCBI Gene 3558], IL4 (interleukin 4) [NCBI Gene 3565], IL5 (interleukin 5) [NCBI Gene 3567], IL10 (interleukin 10) [NCBI Gene 3586], IL13 (interleukin 13) [NCBI Gene 3596], IL17A (interleukin 17A) [NCBI Gene 3605], TNF (tumor necrosis factor) [NCBI Gene 7124], IFNG (interferon gamma) [NCBI Gene 3458]
- **Diseases:** Chronic Rhinosinusitis (MONDO:0006031)

## Full-text entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, IL1RAP (interleukin 1 receptor accessory protein) [NCBI Gene 3556] {aka C3orf13, IL-1RAcP, IL1R3}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** inflammation (MESH:D007249), respiratory disease (MESH:D012140), paranasal sinus inflammatory disease (MESH:D010254), LMS (MESH:C537878), CRS with nasal polyps (MESH:D009298), CRS (MESH:D000092562), AERD (MESH:D018450)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10870654/full.md

---
Source: https://tomesphere.com/paper/PMC10870654